title: The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.
abstract: Clinical outcomes for patients with multiple myeloma (MM) have improved substantially since the introduction of novel agents including the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide. However, most patients with MM eventually relapse, and prognosis remains poor among patients with relapsed and/or refractory disease. Combination therapy using agents with different mechanisms of action is emerging as an attractive treatment approach in oncology to increase efficacy and/or overcome resistance to standard treatment regimens. This review discusses unmet needs in the treatment of MM and the development of histone deacetylase inhibitors as a treatment modality for MM.
authors.affiliation: Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic.
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
authors.forename: David
authors.initials: D
authors.lastname: Siegel
authors.forename: Robert Z
authors.initials: RZ
authors.lastname: Orlowski
authors.forename: Heinz
authors.initials: H
authors.lastname: Ludwig
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
authors.forename: Meletios
authors.initials: M
authors.lastname: Dimopoulos
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality*; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors